Vertex Pharmaceuticals Incorporated
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| VX1.F | 095700.KQ | CSL.AX | KRYS | ROIV | 1530.HK | |
|---|---|---|---|---|---|---|
| Market cap | 115.67B | 115.52B | 94.10B | 9.54B | 26.58B | 35.39B |
| P/E (TTM) | 31.5 | — | — | 40.4 | — | 3.9 |
| Forward P/E | 34.8 | — | 20.6 | 36.0 | -21.4 | 10.5 |
| Price/book | 6.4 | — | 4.4 | 7.0 | 6.3 | 1.1 |
| Dividend yield | — | — | 2.07% | — | — | 1.70% |
| 1-year change | +22.12% | −50.38% | −10.94% | +74.56% | +94.43% | −48.38% |
| Today | +2.52% | −2.31% | −0.11% | −1.00% | +5.38% | −2.79% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All VX1.F news ›AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Choosing between established dividend payers and high-growth innovators is a classic investor dilemma. This comparison pits AbbVie (ABBV +2.26%) against Vertex Pharmaceuticals (VRTX +2.53%) to determine which company offers the best…
Lobbying Update: $1,100,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed
$1,100,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed, from Q3 of 2026, in a new Lobbying Disclosure Act filing. Members of Congress have traded $VRTX stock 1 times in the past 6 months. Of those trades, 0 have been…
3,678 Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Banque Pictet & Cie SA
Posted by Defense World Staff on Oct 17th, 2026 NASDAQ:VRTX opened at $499.74 on Friday. The stock’s fifty day moving average is $523.54 and its 200 day moving average is $480.55. Vertex Pharmaceuticals Incorporated has a fifty-two week…
How Vertex Pharmaceuticals Incorporated (VRTX) Affects Rotational Strategy Timing
Stock Traders Daily Key findings for Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) - Weak Near and Mid-Term Sentiment Could Challenge Long-Term Positive Outlook - Exceptional 25.9:1 risk-reward short setup targets 7.5% downside vs…
Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $654 From $653
www.marketscreener.com Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $654 From $653 Published on 10/15/2026 at 06:40 am EDT
Vertex Pharmaceuticals Says Alyftrek Delivers Pancreatic Function Recovery in Some Children
Vertex Pharmaceuticals said Friday that new interim data from an open-label extension study evaluating Alyftrek in cystic fibrosis showed that some pediatric patients aged 2 to 5 years recovered... Vertex Pharmaceuticals Says Alyftrek…
Vertex Pharmaceuticals Incorporated Presents New Interim Data on Alyftrek in Children Ages 2 to 5 Years At the North American Cystic Fibrosis Conference
Vertex Pharmaceuticals Incorporated announced new interim data from the ALYFTREK® 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children...
DC Circuit Agrees Vertex Pharmaceuticals’ Fertility Support Program Would Violate Anti-Kickback Statute
On September 4, the US Court of Appeals for the DC Circuit ruled that the US Department of Health and Human Services Office of the Inspector General (HHS-OIG) properly found that Vertex Pharmaceuticals’ Fertility Support Program would…
Citi Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)
The Globe and Mail Citi analyst Geoff Meacham maintained a Buy rating on Vertex Pharmaceuticals today and set a price target of $585.00. Meacham covers the Healthcare sector, focusing on stocks such as Amgen, Regeneron, and Bristol-Myers…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
marketscreener.com15
-
fool.com5
-
theglobeandmail.com4
-
gurufocus.com2
-
quiverquant.com2
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 38 articles, not a forecast.